PBX1 as a novel master regulator in cancer : Its regulation, molecular biology, and therapeutic applications
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved..
PBX1 is a critical transcription factor at the top of various cell fate-determining pathways. In cancer, PBX1 stands at the crossroads of multiple oncogenic signaling pathways and mediates responses by recruiting a broad repertoire of downstream targets. Research thus far has corroborated the involvement of PBX1 in cancer proliferation, resisting apoptosis, tumor-associated neoangiogenesis, epithelial-mesenchymal transition (EMT) and metastasis, immune evasion, genome instability, and dysregulating cellular metabolism. Recently, our understanding of the functional regulation of the PBX1 protein has advanced, as increasing evidence has depicted a regulatory network consisting of transcriptional, post-transcriptional, and post-translational levels of control mechanisms. Furthermore, accumulating studies have supported the clinical utilization of PBX1 as a prognostic or therapeutic target in cancer. Preliminary results showed that PBX1 entails vast potential as a targetable master regulator in the treatment of cancer, particularly in those with high-risk features and resistance to other therapeutic strategies. In this review, we will explore the regulation, protein-protein interactions, molecular pathways, clinical application, and future challenges of PBX1.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1879 |
|---|---|
| Enthalten in: |
Biochimica et biophysica acta. Reviews on cancer - 1879(2024), 2 vom: 11. März, Seite 189085 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kao, Ting-Wan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer biology |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 12.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbcan.2024.189085 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368306224 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368306224 | ||
| 003 | DE-627 | ||
| 005 | 20240412232819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240211s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbcan.2024.189085 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM368306224 | ||
| 035 | |a (NLM)38341110 | ||
| 035 | |a (PII)S0304-419X(24)00016-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kao, Ting-Wan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PBX1 as a novel master regulator in cancer |b Its regulation, molecular biology, and therapeutic applications |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a PBX1 is a critical transcription factor at the top of various cell fate-determining pathways. In cancer, PBX1 stands at the crossroads of multiple oncogenic signaling pathways and mediates responses by recruiting a broad repertoire of downstream targets. Research thus far has corroborated the involvement of PBX1 in cancer proliferation, resisting apoptosis, tumor-associated neoangiogenesis, epithelial-mesenchymal transition (EMT) and metastasis, immune evasion, genome instability, and dysregulating cellular metabolism. Recently, our understanding of the functional regulation of the PBX1 protein has advanced, as increasing evidence has depicted a regulatory network consisting of transcriptional, post-transcriptional, and post-translational levels of control mechanisms. Furthermore, accumulating studies have supported the clinical utilization of PBX1 as a prognostic or therapeutic target in cancer. Preliminary results showed that PBX1 entails vast potential as a targetable master regulator in the treatment of cancer, particularly in those with high-risk features and resistance to other therapeutic strategies. In this review, we will explore the regulation, protein-protein interactions, molecular pathways, clinical application, and future challenges of PBX1 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer biology | |
| 650 | 4 | |a Cancer therapy | |
| 650 | 4 | |a PBX1 | |
| 650 | 4 | |a Transcription factor | |
| 650 | 7 | |a Pre-B-Cell Leukemia Transcription Factor 1 |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a PBX1 protein, human |2 NLM | |
| 700 | 1 | |a Chen, Hsiao-Han |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, James |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tian-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yao-An |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochimica et biophysica acta. Reviews on cancer |d 1998 |g 1879(2024), 2 vom: 11. März, Seite 189085 |w (DE-627)NLM097444006 |x 1879-2561 |7 nnns |
| 773 | 1 | 8 | |g volume:1879 |g year:2024 |g number:2 |g day:11 |g month:03 |g pages:189085 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbcan.2024.189085 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1879 |j 2024 |e 2 |b 11 |c 03 |h 189085 | ||